Dry Eyes Clinical Trial
Official title:
Inter and Intra Examiner Reproducibility of LipiView Ocular Surface Interferometer (LipiView) for Measuring Tear Lipid Layer Thickness
Verified date | June 2014 |
Source | Singapore National Eye Centre |
Contact | n/a |
Is FDA regulated | No |
Health authority | Singapore: Health Sciences Authority |
Study type | Interventional |
Dry eye clinical research is limited to follow up of disease progression. While a large
catalogue of tests, such as corneal staining grading, tear break up time (TBUT) and
Schirmer's test, is available, objective assessments demonstrate poor to moderate
repeatability. Among these assessments, TBUT has the best repeatability while the Schirmer's
test shows good repeatability for more severe forms of the disease.1 As such, currently,
most research outcomes are based on subjective patient complaints rather than objective
assessment of the condition.
LipiView Ocular Surface Interferometer (LipiView) is a HSA-approved imaging device that has
the ability to assess optical interference pattern produced by light reflected off the tear
film in a safe and non-invasive manner.2 Software analysis of the image then measures the
tear LLT, which is used to objectively quantify the diagnosis of lipid-deficient dry eye.
This current study aims to investigative the inter and intra-examiner reproducibility of
measuring tear lipid layer thickness (LLT) with LipiView, which is used in our current
clinical setting. LipiView has not been evaluated on its reproducibility of measuring tear
lipid layer thickness. The study will also assess for correlation between the magnitude of
tear LLT and the inter and intra-examiner reproducibility of LipiView.
Once this method is found to be repeatable, this can be used in future clinical settings and
trials as an additional tool to investigate dry eye treatments.
Status | Completed |
Enrollment | 20 |
Est. completion date | February 2014 |
Est. primary completion date | February 2014 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | Both |
Age group | 21 Years to 90 Years |
Eligibility |
Inclusion Criteria: - Volunteers that are medically fit and willing to participate in this study. Exclusion Criteria: - No eye surgery done within the previous 3 months - Active ocular surface conditions such as infection or pterygium that may affect tear film stability. - Any other specified reason as determined by clinical investigator. |
Intervention Model: Single Group Assignment, Masking: Open Label
Country | Name | City | State |
---|---|---|---|
Singapore | Singapore Eye Research Institute | Singapore |
Lead Sponsor | Collaborator |
---|---|
Singapore National Eye Centre |
Singapore,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | The repeatability of objective tear lipid layer thickness measurements of LipiView from the same examiner. | 1 day | No |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT01988597 -
Dry Eye Symptoms and Quality of Life
|
N/A | |
Completed |
NCT01933178 -
Reproducibility of Anterior Segment Optical Coherence Tomography (AS-OCT) for Imaging Conjunctivochalasis
|
N/A | |
Withdrawn |
NCT02123147 -
Examining the Immunological Process of Autoimmune Patients
|
N/A | |
Terminated |
NCT01450787 -
Prevalence of Dry Eyes in Diabetics Compared to Non Diabetics
|
N/A | |
Completed |
NCT06071780 -
Virgin Coconut Oil Contact Lens as Ocular Rewetting Agent
|
N/A | |
Recruiting |
NCT02306668 -
Ocular Surface Dry Eye Microbiome
|
N/A | |
Completed |
NCT01918410 -
Effect of Contact Lens With Alginic Acid in Dry Eye Patients
|
N/A | |
Completed |
NCT01991132 -
Validating the Diagnostic Accuracy of Mediview 2.0 Software as an Image Analysis Tool of Meibomian Glands
|
N/A | |
Completed |
NCT01679015 -
Evaluating Patients With Eye Allergies and Determining if There Are Also Dry Eyes
|
N/A | |
Completed |
NCT01682460 -
Pilot Study on the Use of Artificial Tears to Treat Dry Eye in Glaucoma Patients
|
Phase 4 | |
Completed |
NCT01695668 -
Treatment of Ocular Graft-versus-Host Disease (GVHD) With Topical Loteprednol Etabonate 0.5%
|
N/A | |
Enrolling by invitation |
NCT02153515 -
Treating Dry Eyes and Corneal Ulcers With Fingerprick Autologous Blood
|
Phase 3 |